Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
CEO Jenny Sundqvist gave a very confident impression of why the Conclude phase lll study with Cobitolimod were delayed, how they will speed up the process and what potential triggers to look for in Q4-2023. Further the CEO confirmed earlier estimates for growth in the total addressable UC market.
CDO Dr. Eva Arlander deep dived into the recently announced outcome of the PK-study with Cobitolimod 500 mg dose and how they will use positive data going forward.
Listen to the interview: https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod
Disclaimer:
HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 09:35 AM 03-29-2023.
InDex Pharmaceuticals er en farmaceutisk udviklingsvirksomhed med fokus på immunologiske sygdomme, hvor der er et stort udækket medicinsk behov for nye behandlingsmuligheder. Virksomhedens førende aktiv er lægemiddelkandidaten cobitolimod, som er i et sent stadium i klinisk udvikling til behandling af moderat til svær colitis ulcerosa - en invaliderende, kronisk betændelse i tyktarmen. InDex har også udviklet en platform af patentbeskyttede stoffer i opdagelsesstadiet, såkaldte DNA-baserede ImmunoModulatory Sequences (DIMS), med potentiale til at blive brugt til behandling af forskellige immunologiske sygdomme. InDex er baseret i Stockholm, Sverige. Selskabets aktier (ticker INDEX) handles på Nasdaq First North Growth Market Stockholm.
Read more on company pageForum opdateringer
